Date: 2018-07-18
Type of information: Nomination
Compound: chief medical officer
Company: Tmunity Therapeutics (USA - PA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On July 10, 2018, Tmunity Therapeutics announced the appointment of Christina Coughlin, MD, PhD, as Chief Medical Officer and Executive Vice President. Dr. Coughlin formerly served as Chief Medical Officer at Immunocore, a British biotechnology company, where she was responsible for leading the effort to develop novel bispecific T cell receptor-based biologics for cancer immunotherapy. In her role at Tmunity, Dr. Coughlin will be responsible for clinical development, program leadership and regulatory affairs.
- During her tenure at Immunocore, Dr. Coughlin led the Company’s clinical efforts and developed a pivotal program around the gp100-specific TCR bispecific in uveal melanoma. She previously led early development programs at Novartis, including programs focused on the investigation of checkpoint inhibition and PI3’ kinase inhibition. Dr. Coughlin has both biotechnology and large pharmaceutical industry experience, having held senior medical positions at Morphotek (Eisai), Pfizer and Wyeth.
- Earlier in her career, Dr. Coughlin was a physician-scientist at the University of Pennsylvania and the Children's Hospital of Philadelphia where she studied patient responses to tumor antigens with Dr. Robert Vonderheide in the division of Translational Research under the direction of Dr. June.
- Dr. Coughlin holds a Bachelor of Science degree from Temple University and an MD and PhD from the University of Pennsylvania. She completed her residency and a hematology/oncology fellowship at Children’s Hospital of Philadelphia, as well as a research post-doctoral fellowship at the University of Pennsylvania. Dr. Coughlin was also elected a Fellow of the Royal Society of Medicine (London, UK).
Financial terms:
Latest news:
Is general: Yes
